MARAVAI LIFESCIENCES HLDGS-A (MRVI)

US56600D1072 - Common Stock

5.33  +0.2 (+3.9%)

After market: 5.33 0 (0%)

Fundamental Rating

2

Overall MRVI gets a fundamental rating of 2 out of 10. We evaluated MRVI against 57 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI is valued expensive and it does not seem to be growing.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRVI has reported negative net income.
In the past year MRVI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
MRVI had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of MRVI (-17.58%) is comparable to the rest of the industry.
MRVI has a Return On Equity of -65.09%. This is in the lower half of the industry: MRVI underperforms 71.93% of its industry peers.
Industry RankSector Rank
ROA -17.58%
ROE -65.09%
ROIC N/A
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MRVI has a Gross Margin (46.36%) which is comparable to the rest of the industry.
MRVI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRVI has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRVI has less shares outstanding
MRVI has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.69, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.69, MRVI is in line with its industry, outperforming 45.61% of the companies in the same industry.
MRVI has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.59, MRVI is doing worse than 82.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACC11.4%

2.3 Liquidity

MRVI has a Current Ratio of 10.74. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
MRVI has a better Current ratio (10.74) than 94.74% of its industry peers.
MRVI has a Quick Ratio of 9.94. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
MRVI has a better Quick ratio (9.94) than 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 10.74
Quick Ratio 9.94

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MRVI have decreased strongly by -108.11% in the last year.
MRVI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.99%.
The Revenue has been growing by 18.47% on average over the past years. This is quite good.
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-33.99%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%

3.2 Future

The Earnings Per Share is expected to grow by 36.62% on average over the next years. This is a very strong growth
Based on estimates for the next years, MRVI will show a small growth in Revenue. The Revenue will grow by 6.77% on average per year.
EPS Next Y-379.28%
EPS Next 2Y-93.61%
EPS Next 3Y-35.21%
EPS Next 5Y36.62%
Revenue Next Year-7.11%
Revenue Next 2Y-2.26%
Revenue Next 3Y2.31%
Revenue Next 5Y6.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

MRVI's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 786.1

4.3 Compensation for Growth

MRVI's earnings are expected to decrease with -35.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-93.61%
EPS Next 3Y-35.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (12/24/2024, 7:26:33 PM)

After market: 5.33 0 (0%)

5.33

+0.2 (+3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners91.07%
Inst Owner Change-0.14%
Ins Owners1.36%
Ins Owner Change1.74%
Market Cap1.35B
Analysts80
Price Target9.92 (86.12%)
Short Float %6.61%
Short Ratio4.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-127.49%
Min EPS beat(2)-154.98%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-12.26%
Min EPS beat(4)-154.98%
Max EPS beat(4)182.94%
EPS beat(8)3
Avg EPS beat(8)-52.71%
EPS beat(12)7
Avg EPS beat(12)-29.98%
EPS beat(16)11
Avg EPS beat(16)-16.19%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.38%
Max Revenue beat(2)0.46%
Revenue beat(4)3
Avg Revenue beat(4)2.98%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)12.9%
Revenue beat(8)3
Avg Revenue beat(8)-1.4%
Revenue beat(12)6
Avg Revenue beat(12)-0.2%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)-13.04%
PT rev (3m)-13.17%
EPS NQ rev (1m)-5.45%
EPS NQ rev (3m)-810.63%
EPS NY rev (1m)-80.96%
EPS NY rev (3m)-154.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.56%
Revenue NY rev (1m)-3.94%
Revenue NY rev (3m)-5.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.86
P/FCF N/A
P/OCF 44.98
P/B 3.9
P/tB N/A
EV/EBITDA 786.1
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.12
OCFY2.22%
SpS1.1
BVpS1.37
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.58%
ROE -65.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.36%
FCFM N/A
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Debt/EBITDA 338.66
Cap/Depr 88.87%
Cap/Sales 15.01%
Interest Coverage N/A
Cash Conversion 1850.77%
Profit Quality N/A
Current Ratio 10.74
Quick Ratio 9.94
Altman-Z 1.69
F-Score5
WACC11.4%
ROIC/WACCN/A
Cap/Depr(3y)92.26%
Cap/Depr(5y)89.24%
Cap/Sales(3y)8.83%
Cap/Sales(5y)9.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-379.28%
EPS Next 2Y-93.61%
EPS Next 3Y-35.21%
EPS Next 5Y36.62%
Revenue 1Y (TTM)-33.99%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%
Revenue Next Year-7.11%
Revenue Next 2Y-2.26%
Revenue Next 3Y2.31%
Revenue Next 5Y6.77%
EBIT growth 1Y-153.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200.24%
EBIT Next 3Y64.03%
EBIT Next 5Y48.51%
FCF growth 1Y-102.43%
FCF growth 3Y-21.79%
FCF growth 5YN/A
OCF growth 1Y-93.96%
OCF growth 3Y-6.05%
OCF growth 5YN/A